Literature DB >> 20920497

Use of likelihood ratios improves clinical interpretation of IgG and IgA anti-DGP antibody testing for celiac disease in adults and children.

Pieter Vermeersch1, Thomas Richter, Almuthe C Hauer, Martin Stern, Holm H Uhlig, Klaus-Peter Zimmer, Martin W Laass, Ilse Hoffman, Martin Hiele, Thomas Mothes, Xavier Bossuyt.   

Abstract

OBJECTIVE: To evaluate whether taking into account anti-deamidated gliadin peptide (DGP) antibody concentrations improves clinical interpretation. DESIGN AND METHODS: We calculated likelihood ratios (LR) using data from two previously published studies for assays from EUROIMMUN and INOVA.
RESULTS: LRs markedly increased with increasing IgG anti-DGP concentrations. LRs also increased with increasing IgA anti-DGP concentrations, although they were lower than for IgG anti-DGP.
CONCLUSIONS: Use of LRs for different test result intervals improves clinical interpretation.
Copyright © 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920497     DOI: 10.1016/j.clinbiochem.2010.09.026

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease.

Authors:  Nicholas A Hoerter; Sarah E Shannahan; Jorge Suarez; Suzanne K Lewis; Peter H R Green; Daniel A Leffler; Benjamin Lebwohl
Journal:  Dig Dis Sci       Date:  2017-02-04       Impact factor: 3.199

2.  Likelihood Ratio Approach and Clinical Interpretation of Laboratory Tests.

Authors:  Walter Fierz; Xavier Bossuyt
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

Review 3.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.